First National Bank of Omaha Boosts Stock Holdings in Zoetis Inc. (NYSE:ZTS)

First National Bank of Omaha lifted its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 6.2% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 56,660 shares of the company's stock after buying an additional 3,287 shares during the period. First National Bank of Omaha's holdings in Zoetis were worth $11,070,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Darwin Wealth Management LLC bought a new position in shares of Zoetis during the third quarter valued at $31,000. First Personal Financial Services acquired a new position in Zoetis during the 3rd quarter worth about $33,000. Capital Performance Advisors LLP bought a new stake in shares of Zoetis in the 3rd quarter valued at about $33,000. Dunhill Financial LLC increased its stake in shares of Zoetis by 80.6% in the third quarter. Dunhill Financial LLC now owns 168 shares of the company's stock valued at $33,000 after buying an additional 75 shares during the period. Finally, Quarry LP raised its position in shares of Zoetis by 273.2% during the second quarter. Quarry LP now owns 209 shares of the company's stock worth $36,000 after acquiring an additional 153 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors.

Zoetis Stock Up 1.0 %

ZTS stock traded up $1.69 during trading on Friday, reaching $176.46. 2,551,210 shares of the stock were exchanged, compared to its average volume of 2,537,907. The firm's 50 day moving average is $182.07 and its 200 day moving average is $181.07. The firm has a market cap of $79.61 billion, a P/E ratio of 33.17, a price-to-earnings-growth ratio of 2.88 and a beta of 0.89. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $201.92.

Zoetis (NYSE:ZTS - Get Free Report) last issued its earnings results on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, topping analysts' consensus estimates of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The company had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.29 billion. During the same period in the prior year, the firm earned $1.36 earnings per share. Zoetis's revenue for the quarter was up 11.6% on a year-over-year basis. As a group, research analysts forecast that Zoetis Inc. will post 5.9 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, December 3rd. Stockholders of record on Thursday, October 31st were issued a dividend of $0.432 per share. This represents a $1.73 dividend on an annualized basis and a dividend yield of 0.98%. The ex-dividend date was Thursday, October 31st. Zoetis's dividend payout ratio is currently 32.52%.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. JPMorgan Chase & Co. increased their target price on shares of Zoetis from $225.00 to $230.00 and gave the company an "overweight" rating in a research report on Friday, October 11th. Leerink Partnrs raised shares of Zoetis to a "strong-buy" rating in a research note on Monday, December 2nd. BTIG Research upped their price target on shares of Zoetis from $220.00 to $225.00 and gave the company a "buy" rating in a research report on Monday, August 12th. Piper Sandler lifted their price objective on Zoetis from $195.00 to $210.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 14th. Finally, Leerink Partners began coverage on Zoetis in a research note on Monday, December 2nd. They issued an "outperform" rating and a $215.00 price objective on the stock. Ten equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, Zoetis currently has an average rating of "Buy" and a consensus target price of $219.00.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.